Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. - Wikidata - awgldk - TriplyDB

Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.

Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.

http://www.wikidata.org/entity/Q47361847

about

European evidence based consensus on the diagnosis and management of Crohn's disease: special situations Association of linear growth impairment in pediatric Crohn's disease and a known height locus: a pilot study Review article: Infliximab therapy for inflammatory bowel disease--seven years on Cystic fibrosis and Crohn's disease: successful treatment and long term remission with infliximab.A randomized controlled trial of growth hormone in active pediatric Crohn disease.The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations.Growth problems in children with IBD.Infliximab therapy in pediatric Crohn's disease: a review.Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis Impact of Inflammatory Bowel Disease upon Growth in Children and Adolescents.Growth and bone health in paediatric patients with Crohn's disease receiving subcutaneous tumor necrosis factor antibody.Tumour necrosis factor alpha blockade induces an anti-inflammatory growth hormone signalling pathway in experimental colitis.Growth and Adult Height in Patients with Crohn's Disease Treated with Anti-Tumor Necrosis Factor α Antibodies Control of systemic and local inflammation with transforming growth factor beta containing formulas.Managing complicated Crohn's disease in children and adolescents.Growth retardation in pediatric Crohn's disease: pathogenesis and interventions.Mathematical modelling to restore circulating IGF-1 concentrations in children with Crohn's disease-induced growth failure: a pharmacokinetic study.Infliximab therapy for pediatric Crohn's disease.Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease.Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel disease Early Elevation in Interleukin-6 is Associated with Reduced Growth in Extremely Low Birth Weight Infants.Update on nutritional status, body composition and growth in paediatric inflammatory bowel disease.The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics.Antitumor necrosis factor treatment for pediatric inflammatory bowel disease.Medical therapy for pediatric inflammatory bowel disease.Mucosal healing in Crohn's disease: a systematic review.Advances in the medical management of paediatric IBD.Endocrine therapy for growth retardation in paediatric inflammatory bowel disease.The Role of Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Alpha Agents in Children and Adolescents with Inflammatory Bowel Disease.Early anti-TNF treatment in pediatric Crohn's disease. Predictors of clinical outcome in a population-based cohort of newly diagnosed patients.The effects of recombinant human growth hormone on linear growth in children with Crohn's disease and short stature.Steroid Administration and Growth Impairment in Children with Crohn's Disease.Targeting mucosal healing in Crohn's disease.Infliximab dependency in pediatric Crohn's disease: long-term follow-up of an unselected cohort.Anti-tumor necrosis factor α prevents bowel fibrosis assessed by messenger RNA, histology, and magnetization transfer MRI in rats with Crohn's disease.Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy.Biologic Agents Are Associated with Excessive Weight Gain in Children with Inflammatory Bowel Disease.Association of height with inflammation and periodontitis: the Study of Health in Pomerania.Early Biologic Treatment in Pediatric Crohn's Disease: Catching the Therapeutic Window of Opportunity in Early Disease by Treat-to-Target.Early Infliximab Yields Superior Long-Term Effects on Linear Growth in Pediatric Crohn's Disease Patients.

P2860

Q22242050-591E808F-FC25-4A2E-8204-E360A73D5D97 Q24630823-9EEA4976-DD43-4761-A6C4-A0D65935C564 Q28294134-7E7DE738-30E0-4C31-9B10-73DD02E5EB7F Q33798912-78162300-EBFE-475E-8061-3B98FD435D6C Q34023206-151646DA-75CF-487F-B3FE-3F624944B620 Q34152778-5667E38C-2ABC-449A-B33C-AE4700D8BD37 Q34426164-5D1FF3C7-485F-4FA3-A0D9-966B7D1AF4C4 Q35026358-13168C18-0C73-4DBF-BA17-4EF29624B8B7 Q35637479-8D2E3268-D298-4227-A416-BF8A3DEF8C7C Q35687352-D5157DE7-8E37-4094-948F-77771C69EE56 Q35692293-760345E5-0968-439F-BB7C-E68EF648FC91 Q35761249-2B488772-17CB-4474-88F5-BCAC3C77265A Q36135544-1497123D-A73F-4475-BAF9-7CE57B2EF103 Q36175761-5A10F69E-D743-41F2-8321-8CB5B6587EDF Q36331225-6BBEFF02-1DA4-4034-A283-8E2573FCCCD9 Q36722112-53B9E066-61F8-418C-B208-4041938B7045 Q36876580-7A969596-4916-4BE2-80E1-05446AE76086 Q37012073-6AE474AA-3CC8-4984-BC3D-C1D2456B0EA5 Q37223169-7D57C90B-5DE0-4FE4-8F0D-9290F44533AB Q37609746-2E1ABEE2-0D80-4139-971C-BBCD238C05A7 Q37629942-82117039-95F1-42E6-B28B-5D8E958E5688 Q37660677-265AB924-591C-4E81-AADE-FDBE1022FBCF Q37820898-1DD88ADD-DE4A-49A0-8835-84D8E768982D Q37936394-BFE6552A-589B-4C2A-A8CE-29A861096D3B Q37986622-4A8D9CB7-58F3-47B7-9BA8-782E455FF5D9 Q38005972-AC7EE81C-22C4-4591-8F3F-774E73CDB104 Q38130044-955AB084-41D4-41EA-952B-93E62164A25F Q38137812-3A65EC00-1335-423D-9669-218CA6EF0A91 Q38568813-427AFBFF-F99F-49F4-A6CF-19CE3AD6E5EF Q39114030-D180A64A-48BF-4B4E-A662-49AEB16C7F5F Q40113811-D1957FBA-BDBF-47F2-9148-3E3724DF83DD Q40122541-678D1AED-9FAB-4EF2-9E52-3209704AF982 Q42857508-CDB7ADEF-31A8-4794-B72E-23087CC70052 Q43633425-764F3E18-93B3-4435-9BA6-33049E1359EC Q44132897-7A04353A-7407-4D53-891C-661EB9E3C5AD Q46234832-FD26ED6E-D9B7-44E2-8AB6-8A1B6E83BDDA Q47188554-159FE407-AC90-4093-A2A6-138E06CD829B Q47297535-31A99754-2831-41F0-9516-17CF2B6F628D Q48518781-85B83E0D-A969-49A3-AD61-9E537DA5E236 Q49339951-3407A8BF-F4B6-4337-B9E2-DBF9B9BDBD6F

P2860

Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.

http://www.wikidata.org/entity/Q47361847

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh-hant

name

Infliximab heals intestinal in ...... children with Crohn's disease.

@en

Infliximab heals intestinal in ...... children with Crohn's disease.

@nl

type

label

Infliximab heals intestinal in ...... children with Crohn's disease.

@en

Infliximab heals intestinal in ...... children with Crohn's disease.

@nl

prefLabel

Infliximab heals intestinal in ...... children with Crohn's disease.

@en

Infliximab heals intestinal in ...... children with Crohn's disease.

@nl

P1433

Q47361847-F8A61768-CECB-43EF-8DB9-B5BB958127DA

P1476

Q47361847-33E543EE-634C-4609-B193-9F85EFFCF25A

P2093

Q47361847-3995B6BE-2788-40C5-A56A-B29FB52884EF

Q47361847-3E5F50AC-BAA2-4297-94EC-D99770FD99CF

Q47361847-637576F2-3E8E-4B52-BDD5-58809A3E22FD

Q47361847-C2292A37-47BD-4808-8980-F345A8B9AA07

Q47361847-C46B8733-0E2B-4D10-A9DC-DE418F585AB9

Q47361847-EAEB4C69-8869-45E1-8FBD-90DF9645F538

Q47361847-F829E431-AB2C-4D0B-99E7-6898188B2E8E

P304

Q47361847-87669620-D409-4906-AACE-0801303CE4FB

P31

Q47361847-C21B08B7-3DE7-4D5A-AD51-D3B581430EFB

P356

Q47361847-80391C4B-0663-40E7-9037-9E6A11023A14

P433

Q47361847-AB1EF8FA-DC65-4DCB-AA0E-C5BF92014170

P478

Q47361847-A0BF2548-CEB6-4F89-8B42-C969E9CCB7AA

P50

Q47361847-A4954E9C-AC54-4A93-9BD7-CDDA3340AD34

P577

Q47361847-F1BB32CB-BDFD-4C24-AAB0-2B8514955DC2

P698

Q47361847-25000F3F-0169-4157-93B2-5A1BD8300C09

P356

J.DLD.2003.12.014

P1433

Digestive and Liver Disease

P1476

Infliximab heals intestinal in ...... children with Crohn's disease.

@en

P2093

Barbato M

http://www.w3.org/2001/XMLSchema#string

Bascietto C

http://www.w3.org/2001/XMLSchema#string

Borrelli O

http://www.w3.org/2001/XMLSchema#string

Bosco S

http://www.w3.org/2001/XMLSchema#string

Bueno de Mesquita M

http://www.w3.org/2001/XMLSchema#string

Mancini V

http://www.w3.org/2001/XMLSchema#string

Viola F

http://www.w3.org/2001/XMLSchema#string

P304

342-347

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.DLD.2003.12.014

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P50

Salvatore Cucchiara

P577

2004-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15191204

http://www.w3.org/2001/XMLSchema#string